- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Pipeline Preview
Recent FDA action (through December 2012) related to, Rabeprazole sodium delayed-release sprinkle capsules, CXA-201, CB-215, Buprenorphine subdermal implant, LX1033, ISIS-TTR Rx, Digoxin Immune Fab, Glucagon, AAV1-FS344, Trans sodium crocetinate, Betamethasone valerate foam 0.12%
Priority review
- Rabeprazole sodium (AcipHex, Eisai) delayed-release sprinkle capsules (5 mg and 10 mg) for treatment of gastroesophageal reflux disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children aged 1 to 11 years.
- CXA-201 and CB-315 (Cubist) antibiotics. CXA-201 is being developed as a first-line intravenous treatment for urinary tract infections and complicated intra-abdominal infections. CB-315 is intended for Clostridium difficile-associated diarrhea.
- Buprenorphine (Probuphine, Titan Pharmaceuticals) subdermal implant formulation for the treatment of adult patients with opioid dependence.
Fast-track designations
- LX1033 (Lexicon Pharmaceuticals), an orally-delivered small-molecule candidate, for the treatment of diarrhea-predominant irritable bowel syndrome.
- ISIS-TTR Rx (Isis Pharma/GlaxoSmithKline) for the treatment of familial amyloid polyneuropathy, or FAP.
- Digoxin Immune Fab (Glenveigh Medical) to treat severe preeclampsia.
Orphan drug designations
- Glucagon (Biodel) for the prevention of hypoglycemia in the congenital hyperinsulinism population.
- AAV1-FS344 (Milo Biotechnology), a gene therapy-delivered myostatin inhibitor that increases muscle strength, for the treatment of Duchenne and Becker muscular dystrophy.
- Trans sodium crocetinate (Diffusion Pharmaceuticals) for the treatment of metastatic brain cancer.
First-time generic approval
Betamethasone valerate foam 0.12% (equiv to Luxiq Foam)
perrigo and cobrek pharmaceuticals
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
